Close
  • Home

Archive - August 2020

ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
AbbVie submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) an...
3 October 2025
Regulatory
Enhertu followed by THP supplemental biologics license application accepted in the U.S. for patients with...
3 October 2025
Regulatory
Henlius receives the NMPA IND approval for Its PD-L1 targeting ADC HLX43 in combination with...
3 October 2025
Regulatory
Pyxis Oncology granted FDA Fast Track Designation for PYX-201 monotherapy in patients with recurrent or...
28 February 2025
Regulatory
Hansoh Pharma’s HS-20093 receives Breakthrough Therapy Designation from NMPA for Osteosarcoma
28 February 2025
Regulatory
MHLW (Japan) approved Roche’s Kadcyla for early breast cancer
21 August 2020

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id